
HOUSE COMMITTEE AMENDMENTS

2026 Regular Session

Amendments proposed by House Committee on Insurance to Original House Bill No. 870
by Representative Turner

1 AMENDMENT NO. 12 On page 1, delete lines 12 through 20 and on page 2, lines 1 through 9, and insert in the
3 following definitions in lieu thereof:4 (1) "Biosimilar" means any biological product that is licensed under 42
5 U.S.C. § 262(k) and has been listed in the United States Food and Drug
6 Administration's (FDA) Database of Licensed Biological Products ("Purple Book")
7 as biosimilar to or interchangeable with a reference biological product.8 (2) "Brand drug" means a drug for which an application has been approved
9 under 21 U.S.C. § 355(c), or a biological product, other than a biosimilar, that is
10 licensed under 42 U.S.C. § 262(a).11 (3) "Formulary" means a list of prescription drugs that is developed by a
12 Pharmacy and Therapeutics (P&T) Committee or other clinical and pharmacy
13 experts and represents a health plan's prescription drugs approved for use.14 (4) "Generic drug" means a drug for which an application has been approved
15 under 21 U.S.C. § 355(j) and which has been listed in the United States Food and
16 Drug Administration's Approved Drug Products with Therapeutic Equivalence
17 Evaluations ("Orange Book") as therapeutically equivalent to a reference drug, even
18 if the manufacturer of such drug applies a trade name to the drug.19 (5) "Reference listed drug" is the listed drug identified by the United States
20 Food and Drug Administration as the drug product upon which an applicant relies
21 in seeking approval of its application submitted under 21 U.S.C. § 355(j).22 (6) "Reference product" is a single biological product, licensed by the United
23 States Food and Drug Administration under 42 U.S.C. § 262(a), against which a
24 proposed biosimilar or interchangeable product is compared, and listed as a reference
25 product in the United States Food and Drug Administration's Database of Licensed
26 Biological Products ("Purple Book").27 (7) "Wholesale acquisition cost" has the same definition as "wholesale
28 acquisition cost" in 42 U.S.C. Section 1395w-3a(c)(6)(B).